SPRC Stock: SciSparc Ltd. Stock Price, Analysis & Insights
Get live sprc stock price $3.05, comprehensive SciSparc Ltd. stock analysis, charts, news, and expert forecast. Real-time sprc stock data and investment insights.
Loading chart...
Company Overview
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Company Information
- CEO
- Oz Adler CPA
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
Contact Information
- Website
- https://scisparc.com
- Address
- Tower A
- Country
- IL
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Valuation metrics suggest potential value opportunity (P/E: 0.0)
✓ Higher growth potential with elevated volatility (Beta: 1.22)
Business Model & Strategy
SciSparc Ltd. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Oz Adler CPA, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
SciSparc Ltd. competes in the Biotechnology within the broader Healthcare. With 1.6 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, SciSparc Ltd. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating SciSparc Ltd. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for SciSparc Ltd. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for SciSparc Ltd.
- ⚠Investors should consider how SciSparc Ltd. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
1.59M
P/E Ratio
0.01
Beta
1.22
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 1.59M market capitalization
- Trading Volume: 44.59M shares traded today
- Price Range: 52-week range of $1.75 - $37.59
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for SciSparc Ltd.
SciSparc Ltd. (SPRC) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 1.59M, the company represents a significant player in its market. The stock is currently trading at $3.05 with a positivedaily change of 25.00%.
The company's 2 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 0.01, beta of 1.22, and 52-week price range from $1.75 to $37.59when evaluating investment opportunities.
Why Invest in SciSparc Ltd.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Oz Adler CPA
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.